MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Ken H. Young, Santiago Montes‐Moreno et al.|Blood|2013Cited by 677
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyZijun Y. Xu‐Monette, Ken H. Young, Lin Wu et al.|Blood|2012Cited by 390
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyShimin Hu, Ken H. Young, Zijun Y. Xu‐Monette et al.|Blood|2013Cited by 246
Gene Profiling of Canine B-Cell Lymphoma Reveals Germinal Center and Postgerminal Center Subtypes with Different Survival Times, Modeling Human DLBCLKristy L. Richards, Steven E. Suter, Alison A. Motsinger‐Reif et al.|Cancer Research|2013Cited by 139
Characterizing Canine Lymphoma As a Potential Large Animal Model of Human Diffuse Large B-Cell LymphomaKristy L. Richards, Steven E. Suter, Alison A. Motsinger‐Reif et al.|Blood|2011Cited by 3